El interés en corto de Kindly MD da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Kindly MD. Los datos de interés en corto se actualizan cada dos semanas.

Kindly MD (NASDAQ:KDLY) Bolsa, Informe de interés en corto

Kindly MD

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Kindly MD Inc

<p>Wall Street analysts rerated <strong>Gap, Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) after the company reported upbeat third-quarter print Thursday.</p>
<p>The <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/42141895/whats-going-on-with-gap-shares-friday" rel="noreferrer noopener">company reported sales</a> of $3.829 billion, beating analyst consensus of $3.812 billion. Earnings per share of 72 cents topped analyst estimates of 57 cents.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch" rel="noreferrer noopener">Amazon Strengthens Anthropic Partnership with $8 Billion AI Investment</a></strong></p>
<p>It now expects fiscal 2024 revenue of $15.124 billion &#8211; $15.198 billion, above the consensus of $14.956 billion.</p>
<p>BMO Capital analyst Simeon Siegel maintained Gap with a Market Perform and raised the <a target="_blank" href="https://www.benzinga.com/quote/GAP/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$23&nbsp;to&nbsp;$25</a>.</p>
<p>Telsey Advisory Group analyst Dana Telsey reiterated Gap with a Market Perform and a $26&nbsp;price target.</p>
<p>BofA Securities analyst Lorraine Hutchinson maintained Gap with a Neutral and raised the price target from&nbsp;$25&nbsp;to&nbsp;$28.</p>
<p>Guggenheim analyst Robert Drbul reiterated a Buy rating on Gap with a price target of $35.</p>
<p><strong>BMO Capital:</strong> Gap reported third-quarter EPS that significantly exceeded expectations, with sales slightly surpassing estimates.</p>
<p>Key drivers included robust gross margin improvement, supported by more substantial merchandise margins and ROD leverage. Banana Republic, Gap, and Athleta exceeded expectations, while Old Navy met projections despite weather-related challenges. Management highlighted market share gains across all brands and raised its guidance for full-year sales, gross margin, and EBIT growth.</p>
<p>Old Navy sales were flat year-over-year, marking a moderation from prior quarters but maintaining momentum. Unseasonably warm weather impacted the performance of children&#8217;s apparel, but sales rebounded as weather patterns normalized.</p>
<p>Gap Brand delivered its fourth consecutive quarter of positive comparable sales, growing 3% year-over-year, driven by strong product and marketing execution.</p>
<p>Banana Republic experienced 2% year-over-year growth, with continued emphasis on improving fundamentals and success in the men&#8217;s category.</p>
<p>Athleta achieved its most robust growth in two years, with sales increasing 4% year-over-year. New product launches and marketing resonated with customers, driving share gains.</p>
<p>Gap&#8217;s gross margin reached 42.7%, exceeding the Street&#8217;s 42.1% estimate, with a 140-basis-point year-over-year expansion. 90-basis-point merchandise margin growth and operating leverage were key contributors. However, fourth-quarter gross margins are expected to remain flat when adjusted for ROD deleverage from calendar shifts.</p>
<p><strong>Telsey Advisory Group:</strong> Telsey provided a detailed assessment of Gap following its third-quarter earnings report. The company exceeded expectations across multiple metrics, reflecting strong operational discipline under its new leadership.</p>
<p>Gap has demonstrated clear progress under its strategic focus on operational discipline, inventory efficiency, and brand portfolio growth. However, the analyst cautions that sustained consistency in performance and long-term profitability will be critical for investor confidence. The positive momentum in sales and profitability efforts suggests Gap is stabilizing its business and positioning itself for future growth.</p>
<p>The price target is based on an 11.5x multiple of the two-year forward EPS estimate of $2.26. While this valuation is slightly below Gap&#8217;s historical average of 13.1x, it reflects the company&#8217;s ongoing challenges in a competitive retail environment.</p>
<p><strong>BofA Securities:</strong> Hutchinson highlighted its sales and margin performance while cautioning about future margin expansion.</p>
<p>Gap delivered adjusted EPS of $0.72, outperforming Hutchinson&#8217;s estimate of $0.54 and the consensus projection of $0.57. The beat was supported by 1.6% sales growth, gross margin improvement, and effective SG&amp;A management. Comps were positive at Athleta (+5%) and Gap (+3%). Management raised its fiscal 2024 guidance, reflecting the third-quarter outperformance.</p>
<p>Hutchinson raised fiscal 2024 and fiscal 2025 EPS estimates by 9% and 5%, respectively, projecting $1.97 and $1.99. The analyst increased the price target to $28, based on a 6x 2025 estimated EV/EBITDA.</p>
<p>Management raised its fiscal 2024 guidance for sales, gross margin, and operating income. Hutchinson expects gross margin to improve by 350 basis points compared to 2019, driven by reduced promotions and more vital full-price selling.</p>
<p>However, Hutchinson highlighted that while Gap has achieved significant cost savings, management may prioritize reinvesting efficiencies into growth initiatives and inflation offsets rather than improving the bottom line.</p>
<p>Hutchinson&#8217;s price target of $28 reflects a 6x 2025 estimated EV/EBITDA, consistent with peer averages. This valuation balances risks tied to Gap&#8217;s exposure to low-income consumers and freight costs against its turnaround potential and Athleta&#8217;s relatively more robust performance.</p>
<p>While Hutchinson acknowledges the company&#8217;s improved sales trajectory, remains cautious on further margin growth.</p>
<p><strong>Guggenheim: </strong>Drbul highlighted the company&#8217;s earnings beat, strategic progress, and upwardly revised guidance. The quarter marked the company&#8217;s fourth consecutive quarter of top-line growth and seventh quarter of market share gains.</p>
<p>Drbul values Gap at 15.2x 2025 EPS, a premium to its five-year average multiple of 12.5x, reflecting confidence in ongoing operational improvements and growth potential.</p>
<p>He highlighted the strength of the Old Navy and Athleta brands as critical drivers, particularly noting Athleta&#8217;s position in an attractive apparel segment. With a ~3% dividend yield, Drbul views Gap shares as offering a compelling risk-reward profile supported by significant asset value and strategic optionality.</p>
<p>Drbul&#8217;s price target underscores optimism about Gap&#8217;s ability to sustain its momentum, deliver margin expansion, and execute its reinvigoration initiatives successfully.</p>
<p><strong>Price Action:</strong> GAP stock is up 11.2% at $24.51 at last check Friday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42140725/snap-denies-facilitating-child-exploitation-seeks-dismissal-of-state-lawsuit" target="_blank" rel="noreferrer noopener">Snap Denies Child Exploitation Allegations, Wants Lawsuit Dismissed</a></strong></li>
</ul>


Analyst Color

Equities

News

Price Target

Reiteration

Analyst Ratings

Trading Ideas

Gap's Growth Drivers: Market Share Gains, Brand Momentum, And Raised Guidance – Analysts Weigh In

<p>A recent study <a href="https://www.nature.com/articles/s41598-024-79931-w">published</a> in Scientific Reports explores the strategies individuals use to navigate challenging psychedelic experiences and how these responses relate to emotional breakthroughs. Researchers from University College London conducted a mixed-methods investigation, combining qualitative analyses of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> retreat participants&#8217; experiences with a broader survey involving 529 individuals who reported past psychedelic use.</p>
<h3 class="wp-block-heading"><strong>Three Core Strategies Identified</strong></h3>
<p>The study developed the <strong>Responses to Challenging Psychedelic Experiences Inventory</strong> (ReCiPE), revealing three key coping strategies:</p>
<ul>
<li><strong>Acceptance and Reappraisal</strong>: Emphasizing surrender and acceptance of the experience, this approach was most strongly associated with emotional breakthroughs.</li>
<li><strong>Sensory Regulation and Physical Interaction</strong>: Strategies such as intentional breathing, movement or environmental engagement helped participants manage distress.</li>
<li><strong>Social Support and Disclosure</strong>: Seeking help or sharing experiences with others proved beneficial, reinforcing the role of interpersonal dynamics during challenging moments.</li>
</ul>
<h3 class="wp-block-heading"><strong>Fear Vs. Breakthroughs</strong></h3>
<p>The research found that not all challenges led to positive outcomes. Fear-related experiences often hindered emotional breakthroughs, whereas grief and death-related challenges were more likely to result in transformative insights. This suggests that the type of distress experienced during a psychedelic session plays a significant role in determining therapeutic outcomes.<br /></p>
<p><strong><em>See also:</em></strong><em> </em><a href="https://www.benzinga.com/markets/cannabis/23/06/32800473/psychedelic-trip-dos-and-donts-what-to-avoid-during-your-psychedelic-experience"><em>Psychedelic Trip Do&#8217;s And Don&#8217;ts: What To Avoid During Your Psychedelic Experience</em></a></p>
<h3 class="wp-block-heading"><strong>Implications For Psychedelic-Assisted Therapy</strong></h3>
<p>The findings highlight the importance of equipping individuals with adaptive coping strategies, particularly through acceptance-based approaches such as mindfulness or Acceptance and Commitment Therapy. Tailored interventions that address fear and promote cognitive reappraisal could enhance the safety and efficacy of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapies</a>.</p>
<p>As the study authors conclude, "The paradoxical positive therapeutic role of challenging psychedelic experiences may depend on the kind of challenge faced and the individual's ability to employ adaptive response strategies."</p>
<p><em>Cover image made with AI</em></p>


Cannabis

Psychedelics

How To Navigate Difficult Psychedelic Journeys: Research Insights

WIIM

UPXI

Upexi shares are trading higher. The company announced it received a Non Compliance letter from the Nasdaq.

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Astera Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Astera Labs.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $104,790, and 5 are calls, for a total amount of $588,530.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $110.0 for Astera Labs during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Astera Labs's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Astera Labs's significant trades, within a strike price range of $90.0 to $110.0, over the past month.</p>
<h3>Astera Labs 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732303890_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.7</td>
<td>$10.6</td>
<td>$11.3</td>
<td>$110.00</td>
<td>$394.3K</td>
<td>1.8K</td>
<td>2.1K</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.5</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$105.00</td>
<td>$64.7K</td>
<td>1.6K</td>
<td>295</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.2</td>
<td>$10.0</td>
<td>$10.1</td>
<td>$110.00</td>
<td>$50.5K</td>
<td>1.8K</td>
<td>2.2K</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$20.6</td>
<td>$20.6</td>
<td>$90.00</td>
<td>$49.4K</td>
<td>2.2K</td>
<td>35</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$105.00</td>
<td>$35.0K</td>
<td>246</td>
<td>120</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.</p>
<p>After a thorough review of the options trading surrounding Astera Labs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Astera Labs Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,309,533, the price of ALAB is up by 1.1%, reaching $105.27.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 122 days from now.</li>
</ul>
<h3>Expert Opinions on Astera Labs</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $101.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on Astera Labs with a target price of $100.<br />
&#x2A; An analyst from Citigroup downgraded its action to Buy with a price target of $120.<br />
&#x2A; Maintaining their stance, an analyst from Craig-Hallum continues to hold a Buy rating for Astera Labs, targeting a price of $105.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Astera Labs, which currently sits at a price target of $87.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Astera Labs, which currently sits at a price target of $94. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Astera Labs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

ALAB

Astera Labs Options Trading: A Deep Dive into Market Sentiment

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>NIO</strong>.</p>
<p>Looking at options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) we detected 22 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 4% of the investors opened trades with bullish expectations and 90% with bearish.</p>
<p>From the overall spotted trades, 17 are puts, for a total amount of $1,002,691 and 5, calls, for a total amount of $164,560.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $4.0 and $20.0 for NIO, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for NIO's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NIO's whale activity within a strike price range from $4.0 to $20.0 in the last 30 days. </p>
<h3>NIO Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732303885_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.9</td>
<td>$3.95</td>
<td>$8.00</td>
<td>$129.1K</td>
<td>17.6K</td>
<td>881</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.95</td>
<td>$8.00</td>
<td>$83.6K</td>
<td>17.6K</td>
<td>3.9K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.95</td>
<td>$8.00</td>
<td>$78.9K</td>
<td>17.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.92</td>
<td>$8.00</td>
<td>$68.8K</td>
<td>17.6K</td>
<td>1.5K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.67</td>
<td>$0.65</td>
<td>$0.67</td>
<td>$5.00</td>
<td>$67.0K</td>
<td>63.0K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About NIO</h3>
<p>Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.</p>
<p>In light of the recent options history for NIO, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is NIO Standing Right Now?</h3>
<ul>
<li>With a volume of 45,538,092, the price of NIO is up 3.4% at $4.86. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 102 days.</li>
</ul>
<h3>What The Experts Say On NIO</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $5.699999999999999.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Macquarie has revised its rating downward to Neutral, adjusting the price target to $4.<br />
&#x2A; An analyst from Macquarie has elevated its stance to Outperform, setting a new price target at $6. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NIO options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


NIO Unusual Options Activity For November 22

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>United Airlines Holdings</strong>.</p>
<p>Looking at options history for United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) we detected 18 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations and 44% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $235,826 and 11, calls, for a total amount of $525,405.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $130.0 for United Airlines Holdings during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for United Airlines Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Airlines Holdings's whale activity within a strike price range from $40.0 to $130.0 in the last 30 days. </p>
<h3>United Airlines Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732303880_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$21.2</td>
<td>$19.1</td>
<td>$21.2</td>
<td>$92.50</td>
<td>$169.6K</td>
<td>7</td>
<td align="right">81</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$35.75</td>
<td>$35.45</td>
<td>$35.75</td>
<td>$60.00</td>
<td>$53.6K</td>
<td>2.7K</td>
<td align="right">27</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.2</td>
<td>$13.1</td>
<td>$13.1</td>
<td>$95.00</td>
<td>$44.5K</td>
<td>646</td>
<td align="right">0</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$1.94</td>
<td>$1.42</td>
<td>$1.94</td>
<td>$94.00</td>
<td>$38.8K</td>
<td>599</td>
<td align="right">288</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$25.3</td>
<td>$24.95</td>
<td>$25.25</td>
<td>$75.00</td>
<td>$37.8K</td>
<td>2.1K</td>
<td align="right">48</td>
</tr>
</tbody>
</table>
</p>
<h3>About United Airlines Holdings</h3>
<p>United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.</p>
<p>Following our analysis of the options activities associated with United Airlines Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of United Airlines Holdings</h3>
<ul>
<li>Trading volume stands at 4,166,913, with UAL's price down by -0.79%, positioned at $93.65.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 60 days.</li>
</ul>
<h3>Professional Analyst Ratings for United Airlines Holdings</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $131.33333333333334.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on United Airlines Holdings, which currently sits at a price target of $150.<br />
&#x2A; Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Buy with a new price target of $119.<br />
&#x2A; An analyst from TD Cowen persists with their Buy rating on United Airlines Holdings, maintaining a target price of $125. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United Airlines Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With UAL

<p><a href="https://news.alaskaair.com/destinations/alaska-airlines-unveils-top-fall-travel-trends-and-unique-destinations/" title="https://news.alaskaair.com/destinations/alaska-airlines-unveils-top-fall-travel-trends-and-unique-destinations/">https://news.alaskaair.com/destinations/alaska-airlines-unveils-top-fall-travel-trends-and-unique-destinations/</a></p>


Events

Alaska Air Group Says "Thanksgiving Remains The Busiest Travel Period Of The Fall With Flights Projected To Be Nearly Full. We Estimate Nearly 500K Guests Will Fly Between Friday And Sunday With Dec. 1 Expected To Be The Busiest Day Of The Entire Year. Across Our Major West Coast Hubs, We Expect To Fly More Passengers Than Last Year"

<p><a href="https://www.n-tv.de/politik/Stehen-kurz-vor-Loesung-mit-China-um-Zoelle-abzuschaffen-article25381322.html" title="https://www.n-tv.de/politik/Stehen-kurz-vor-Loesung-mit-China-um-Zoelle-abzuschaffen-article25381322.html">https://www.n-tv.de/politik/Stehen-kurz-vor-Loesung-mit-China-um-Zoelle-abzuschaffen-article25381322.html</a></p>


Macro Economic Events

Global

Economics

XPEV

Chair Of European Parliament Trade Committee Tells German Broadcaster NTV, "We Are Close To Agreement With China To Abolish Electric Vehicle Import Tariffs"

<p>October was a strong month for the gaming industry, with eight of the top ten best-selling games in the <a href="https://www.benzinga.com/topic/video-games">U.S. being new releases</a>.</p>
<p>Call of Duty: Black Ops 6 topped the charts, contributing to a 10% year-over-year increase in U.S. video game spending, which reached $4.7 billion.</p>
<p>According to Circana&#8217;s monthly report (<a href="https://www.ign.com/articles/october-2024-sales-charts-call-of-duty-black-ops-6-sparks-xbox-game-pass-subscription-surge">via</a> IGN), Black Ops 6 is already the third best-selling game of the year and saw sales 23% higher in its first two weeks than last year's Modern Warfare 3 over the same period. </p>
<p><strong>See Also:<a href="https://www.benzinga.com/general/gaming/24/11/42141838/elden-ring-creator-hidetaka-miyazaki-teases-various-new-projects-in-development"> Elden Ring Creator Hidetaka Miyazaki Teases &#8216;Various New Projects&#8217; In Development</a></strong></p>
<p><strong>Mat Piscatella</strong> of Circana noted that 82% of the game's full dollar sales came from PlayStation 5, likely because Xbox players opted to access the game through Game Pass instead of purchasing it outright.</p>
<h3 class="wp-block-heading">Game Pass And Subscription Growth</h3>
<p>The availability of <a href="https://www.benzinga.com/general/gaming/24/10/41662426/black-ops-6-shatters-records-call-of-dutys-biggest-launch-drives-60-sales-spike">Black Ops 6 on Game Pass</a> appears to have driven growth in video game subscription spending, which increased 16% year-over-year in October. </p>
<p>This suggests that the game attracted new subscribers to <strong>Microsoft Corp.</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) platform while maintaining strong sales elsewhere.</p>
<h3 class="wp-block-heading">Dragon Ball And Silent Hill Stand Out</h3>
<p>Dragon Ball: Sparking! Zero secured the second spot on October's sales charts and became the best-selling Dragon Ball game in the U.S. The game is also now the third best-selling title in <strong>Bandai Namco Holdings ADR&#8217;</strong>s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NCBDY#OTC">NCBDY</a>) history, following<a href="https://www.benzinga.com/general/gaming/24/11/42068231/sony-in-talks-to-acquire-elden-ring-publisher-kadokawa-report"> Elden Ring </a>and Dark Souls 3.</p>
<p>The Silent Hill 2 remake came in third and is now the second best-selling game in the franchise, second only to the original Silent Hill 2.</p>
<h3 class="wp-block-heading">Sales Shifts from Discounts and Game Pass</h3>
<p>The Final Fantasy I-VI Collection moved up from No. 90 in September to No. 19 in October, likely due to a significant price drop on <strong>Nintendo ADR</strong>&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) Nintendo Switch. Meanwhile, Sifu climbed to No. 9 on Xbox's monthly active users chart after being added to Game Pass.</p>
<h3 class="wp-block-heading">Hardware And Accessories Performance</h3>
<p>Hardware sales saw a 23% decline compared to last year. Nintendo Switch sales dropped 38%, while PlayStation 5 and Xbox Series sales were down 20% and 18%, respectively. The PlayStation 5 remains the top-selling console in both units and dollar sales, with Xbox Series consoles in second place.</p>
<p>In accessories, spending increased by 15%, with <strong>Sony Group Corp</strong>'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) PlayStation Portal becoming the month's best-selling item.</p>
<h3 class="wp-block-heading">Top 20 Best-Selling Games In October</h3>
<ol>
<li>Call of Duty: Black Ops 6</li>
<li>Dragon Ball: Sparking! Zero</li>
<li>Silent Hill 2</li>
<li>Undisputed</li>
<li>Metaphor: ReFantazio</li>
<li>Dragon Age: The Veilguard</li>
<li>Super Mario Party Jamboree!&#x2A;</li>
<li>Madden NFL 25</li>
<li>Sonic X Shadow Generations</li>
<li>EA Sports FC 25</li>
<li>EA Sports College Football 25</li>
<li>The Legend of Zelda: Echoes of Wisdom&#x2A;</li>
<li>Hogwarts Legacy</li>
<li>NHL 25</li>
<li>Astro Bot</li>
<li>Minecraft&#x2A;</li>
<li>NBA 2K25</li>
<li>Life Is Strange: Double Exposure</li>
<li>Final Fantasy I-VI Bundle</li>
<li>Elden Ring</li>
</ol>
<p>(&#x2A;Digital sales data for some titles are not included in Circana's report.)</p>
<p>As the year approaches its final months, upcoming Black Friday deals may impact both hardware and software sales.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42144628/gta-6-trailer-2-fans-frustrated-as-rockstar-possibly-breaks-moon-theory">GTA 6 Trailer 2 Fans Frustrated As Rockstar Possibly Breaks Moon Theory</a></li>
</ul>
<p><em>Image credits: Shutterstock.</em></p>


MSFT

NCBDY

NTDOY

Sony Group Corporation American Depositary Shares

SONY

Call Of Duty: Black Ops 6 Leads Video Game October Sales In The US

<p>U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining by more than 350 points on Friday.</p>
<p>The Dow traded up 0.82% to 44,228.50 while the NASDAQ rose 0.14% to 18,998.27. The S&amp;P 500 also rose, gaining, 0.31% to 5,966.91.</p>
<p>Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></p>
<p><strong>Leading and Lagging Sectors</strong><br /><br />Consumer staples shares rose by 1.5% on Friday.</p>
<p>In trading on Friday, communication services shares fell by 0.6%.</p>
<p><strong>Top Headline</strong></p>
<p>Shares of <strong>Intuit Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell over 5% on Friday after the company reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.</p>
<p>The company reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35 per share. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion</p>
<p><strong>Equities Trading UP</strong><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<ul>
<li><strong>Elastic N.V. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares shot up 16% to $109.17 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Shares of <strong>Matthews International Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) got a boost, surging 19% to $30.26 following upbeat earnings.</li>
<li><strong>Replimune Group, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 45% to $16.00 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
<p><strong>Equities Trading DOWN</strong></p>
<ul>
<li><strong>Autonomix Medical, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 55% to $6.11 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of <strong>Aptose Biosciences Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 43% to $0.1390 after the company announced the pricing of an $8 million public offering.</li>
<li><strong>Cemtrex, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 41% to $0.1164 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
<p><strong>Commodities</strong><br /><br />In commodity news, oil traded up 1.5% to $71.16 while gold traded up 1.1% at $2,704.00.</p>
<p>Silver traded up 1.1% to $31.275 on Friday, while copper fell 0.8% to $4.0940.</p>
<p><strong>Euro zone</strong></p>
<p>European shares were higher today. The eurozone's STOXX 600 rose 1.12%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.46%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 gained 1.35%.</p>
<p>The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.</p>
<p><strong>Asia Pacific Markets</strong></p>
<p>Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.</p>
<p><strong>Economics</strong></p>
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
<p>Now Read This: <a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></p>


Earnings

AMIX

APTO

CETX

ESTC

INTU

MATW

REPL

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

KSCP

Knightscope shares are trading lower after the company announced a proposed public offering of Class A common stock and pre-funded warrants to address working capital needs.

<p><strong>Medtronic's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 4.76% since its last report. The company recently reported that it has <strong>10.18 million shares sold short</strong>, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.93 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732302924_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.17%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Looking Into Medtronic's Recent Short Interest

<p><strong>UP Fintech Holding's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NYSE">TIGR</a>) short percent of float has fallen 25.28% since its last report. The company recently reported that it has <strong>6.07 million shares sold short</strong>, which is 4.73% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>UP Fintech Holding Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732302919_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for UP Fintech Holding has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing UP Fintech Holding's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UP Fintech Holding's peer group average for short interest as a percentage of float is 2.77%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


TIGR

Looking Into UP Fintech Holding's Recent Short Interest

<p><strong>DuPont de Nemours's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) short percent of float has risen 3.03% since its last report. The company recently reported that it has <strong>3.76 million shares sold short</strong>, which is 1.02% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.73 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>DuPont de Nemours Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732302913_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for DuPont de Nemours has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing DuPont de Nemours's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DuPont de Nemours's peer group average for short interest as a percentage of float is 3.19%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into DuPont de Nemours's Recent Short Interest

<p><strong>SoundHound AI, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares are trading higher on Friday. The company announced the deployment of its conversational AI agent, Amelia at Apivia Courtage, as part of the AEMA Group. Here&#8217;s <a href="https://www.benzinga.com/quote/SOUN/news">what you need to know.</a></p>
<p><strong>What To Know:</strong> In a press release on Thursday, SoundHound AI reported that Amelia AI agents managed over 100,000 customer calls in 2024, reducing the volume of inbound queries handled by human employees at Apivia Courtage by nearly 20%. These calls were largely focused on medical expense reimbursements and insurance policy information. The deployment, which began in Jan. 2023, was designed to improve efficiency and allow customer service teams to focus on higher-value tasks.</p>
<p>The CEO of Apivia Courtage, <strong>Emmanuelle Nguyen</strong>, stated that integrating the AI system enhanced work quality for employees and improved workplace atmosphere. <strong>Michael Anderson</strong>, EVP of Enterprise at SoundHound AI, emphasized the benefits of automation in enabling contact center staff to manage more complex tasks.</p>
<p>&#8220;With AI agents managing routine customer questions, Apivia Courtage&#8217;s employees are now able to focus on more rewarding and valuable aspects of their work. We&#8217;re thrilled to support them in delivering thousands of high-quality interactions,&#8221; commented Anderson.</p>
<p>Apivia Courtage, operating under the AEMA Group, is one of France&#8217;s largest insurance entities, serving over 11 million customers through more than 1,600 agencies and 3,900 brokers. The group&#8217;s annual revenue exceeds €15 billion.</p>
<p>&#8220;Projects like this really show the incredible value AI and automation can deliver, not only to our customers but also to their customers,&#8221; said Anderson.</p>
<p><strong>SOUN Price Action:</strong> SoundHound AI shares were up 20.6% at $8.41 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133150/OSUNS-1024x532.png" alt="" class="wp-image-661538" style="width:453px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133150/OSUNS-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133150/OSUNS-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133150/OSUNS-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22133150/OSUNS.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><em>Image Via Shutterstock.</em></p>


Movers

SOUN

SoundHound AI Shares Are On The Rise Friday: What's Going On?

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and lowered the price target from $170 to $105.

Celestica shares are trading lower after UBS initiated coverage on the stock with a Neutral rating and announced a price target of $95.

Best Buy shares are trading higher after JP Morgan maintained an Overweight rating on the stock and raised its price target from $111 to $117.

DOCU

DocuSign shares are trading higher after JMP Securities maintained a Market Outperform rating on the stock and raised its price target from $84 to $108.

CRNC

Cerence shares are trading higher after Craig-Halum maintained a Hold rating on the stock and raised its price target from $3.5 to $6.

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Though <strong>Reddit</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/rddt-stock-quote/"><strong>RDDT</strong></a></span>) may have been the most recent big-name IPO, the initial listings market is still cooking, and undervalued IPO stocks abound. The last undervalued IPO stock I picked at the <a href="https://investorplace.com/2024/06/penny-stocks-that-pack-a-punch-3-names-to-ride-for-10x-gains/">beginning of June,</a> <strong>Nano Nuclear</strong> <strong>Energy </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/"><strong>NNE</strong></a>), returned over 300% since I first noticed it, further proving that undervalued IPO stocks are out there if you know where to look.</p>



<p>In general, the wider IPO market is improving as the year&rsquo;s first half saw <a href="https://www.ey.com/en_gl/insights/ipo/trends">86 U.S.-based IPOs</a> raise nearly $18 billion, a 12% and 67% improvement, respectively, compared to 2024&rsquo;s first half. That does, of course, still pale compared to 2021&rsquo;s shockingly high IPO rates that raised more than $450 globally, but still far better than last year as economic conditions soften. This, of course, benefits undervalued IPO stocks as many still shy away from their inherent &ldquo;opening day&rdquo; risk. These undervalued IPOs often fly under the radar as investors focus primarily on tech and mega-caps &mdash; but that doesn&rsquo;t detract from their long-term upside.</p>



<h2><strong>Viking Holdings (VIK)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/vik1600-300x169.png" alt="MV Viking Star in North Sea Canal. Detail of funnel. VIK stock and VIK IPO"><div>Source: StudioPortoSabbia / Shutterstock.com</div></div><p><strong>Viking Holdings</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/vik-stock-quote/"><strong>VIK</strong></a></span>) is an undervalued IPO stock operating within a segment that&rsquo;s been beaten down in recent years but is due for a resurgence: luxury cruising and passenger transport. The cruise liner stock accomplishes this with a fleet of almost 100 small, high-tech ships. Viking is the largest undervalued IPO stock on our list at a $14.35 billion market cap and the company&rsquo;s shares jumped nearly 40% since first listing in May.</p>



<p>The company&rsquo;s <a href="https://d1io3yog0oux5.cloudfront.net/_d2eabbad631141770d0deb474fe836e3/vikingcruises/db/947/9193/presentation/Earnings+Presentation.pdf">waterborne operations</a> primarily focus on river boating, with 80 existing vessels and 18 more to be delivered in the next two years. But Viking is increasing its oceanic presence and will augment its existing nine seafaring ships with eight more by the end of the decade. Viking seeks to differentiate itself from most cruise liners, which emphasizes partying and ship-centric activities rather than destination arrival. A generally youth-skewing crowd says that &ldquo;Vikings are contrarians, and hence, from the beginning, the vision has been to build a different cruise line.&rdquo; This led Viking to emphasize &ldquo;quiet, understated elegance&rdquo; and a destination focus that targets older demographics of 55+.</p>



<p>Viking&rsquo;s financials already point to a sector-wide turnaround, with revenue improving 14% year-over-year between the first quarters of 2024 and 2023. Expect these tailwinds to continue as the undervalued IPO stock sets sail.</p>



<h2><strong>Proficient Auto Logistics (PAL)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/10/danaos-dac-shipping-transportation-1600-300x169.jpg" alt="A photo of a large shipping vessel at sea."><div>Source: Daniel Wright98 / Shutterstock.com</div></div><p><strong>Proficient Auto Logistics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pal-stock-quote/"><strong>PAL</strong></a></span>) operates within a logistics and transportation segment that&rsquo;s nearly impossible to replace or substitute: vehicular transport, as in the type that brings cars from manufacturers to dealerships, ports and railyards. The company&rsquo;s IPO is unique in that it was a merger of five existing companies under a single umbrella that went public, with shares climbing about 8% since the IPO.</p>



<p>Proficient Auto&rsquo;s <a href="https://proficientautologistics.com/investor-relations/">customer list</a> is a who&rsquo;s who of manufacturers and includes <strong>Tesla</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tsla-stock-quote/"><strong>TSLA</strong></a></span>), <strong>General Motors</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/gm-stock-quote/"><strong>GM</strong></a></span>), <strong>Stellantis</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/stla-stock-quote/"><strong>STLA</strong></a></span>) and <strong>Rivian</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rivn-stock-quote/"><strong>RIVN</strong></a></span>). Though some car manufacturers, like Tesla, prefer to vertically integrate their value chain as much as possible, logistics of this type tends to be a bridge too far from a pricing and resource management perspective, so Proficient Auto has plenty of business in its future.</p>



<p>Proficient saw its net deliveries slump in 2023 amid labor strikes at General Motors and Stellantis and generally reduced consumer interest in car purchases. But that downward trend is already reversing as the company&rsquo;s total units delivered increased by 2% in this year&rsquo;s <a href="https://proficientautologistics.com/wp-content/uploads/2024/06/Earnings-Release-for-Website.pdf">first quarter</a> report &mdash; expect that upward momentum to continue throughout the year as Proficient realizes synergies it created through combining multiple companies and generally improving its own internal processes.</p>



<h2><strong>KindlyMD (KDLY)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks. Healthcare Stocks to Buy"><div>Source: metamorworks / Shutterstock</div></div><p>I want to first acknowledge that, among these undervalued IPO stocks, <strong>KindlyMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/kdly-stock-quote/"><strong>KDLY</strong></a>) trades firmly in penny stock territory at less than $3 per share and a meager $15 million market cap. However</span>, its small size makes KindlyMD&rsquo;s undervalued IPO prospects more appealing. The company operates at the forefront of two unique trends: medical cannabis, which is ready to boom, and <a href="https://kindlymd.com/about-us/">holistic treatments</a> that blend prescription medication, behavioral and mental therapy and alternative solutions that &ldquo;treat the whole person, not just their symptoms.&rdquo;</p>



<p>KindlyMD&rsquo;s first <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8925359497374292">earnings report</a> came shortly after its IPO, and top-line numbers were considerably low at just $829,000 in revenue. But that slim sales stat is, practically speaking, a short-term hurdle toward long-term success. Specifically, KindlyMD hit a range of benchmarks that all but assure expansion and growth in the coming years. That includes becoming Utah&rsquo;s first alternative medicine company to contract under the state&rsquo;s insurance, including Medicare/Medicaid. It contracted with mega-insurer federation <strong>Blue Cross Blue Shield</strong> and secured 16% of Utah&rsquo;s current total addressable medical cannabis market. Better yet, for cannabis stock enthusiasts, KindlyMD and <strong>Curaleaf</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/curlf-stock-quote/"><strong>CURLF</strong></a></span>) started a <a href="https://www.marketscreener.com/quote/stock/KINDLY-MD-INC-170748083/news/KindlyMD-Collaborates-with-Curaleaf-to-Expand-Patient-Education-on-Medical-Cannabis-Care-in-Utah-46945278/">collaboration</a> to expand awareness of alternative treatment opportunities throughout Utah.</p>



<p><em>On the date of publication, Jeremy Flint held no positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a></em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Jeremy Flint, an MBA graduate and skilled finance writer, excels in content strategy for wealth managers and investment funds. Passionate about simplifying complex market concepts, he focuses on fixed-income investing, alternative investments, economic analysis, and the oil, gas, and utilities sectors. Jeremy&rsquo;s work can also be found at <a href="https://jeremyflint.work/">www.jeremyflint.work</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-ipo-gems-flying-under-the-radar-for-now/">3 IPO Gems Flying Under the Radar (for Now)</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 IPO Gems Flying Under the Radar (for Now)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>With the federal government moving to <a href="https://www.forbes.com/sites/dariosabaghi/2024/05/22/dea-publishes-proposed-rules-to-reschedule-marijuana/?sh=57e2057e48e8">reschedule</a> cannabis to Schedule III, effectively paving the way for medical cannabis legalization, <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> are in the spotlight. Cannabis stocks initially spiked on the news but quickly returned to previous levels. This tempered response reflects concerns about the potential disruption a medical cannabis mandate might bring, creating uncertainty that has made investors hesitant to commit to specific cannabis stocks at this moment. Still, tailwinds are gathering behind small and large cannabis stocks alike, creating a unique opportunity to capture upside as some cannabis stocks approach 52-week lows &mdash; or worse.</p>



<p>Ultimately, these cannabis stocks corner a unique segment in a crowded sector, creating an upside of their own based on fundamental and operational strength. Still, they&rsquo;ve fallen prey to wider uncertainty about cannabis stocks more broadly, even as they buck wider trends that include poor distribution channels, limited marketing opportunities and concerns surrounding banking.</p>



<h2><strong>Tilray</strong>&nbsp;(TLRY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/shutterstock_1904349628-300x169.png" alt="Closeup of mobile phone screen with logo lettering of cannabinoid company tilray cannabis, blurred marijuana and pipette background"><div>Source: Ralf Liebhold / Shutterstock.com</div></div><p><strong>Tilray</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tlry-stock-quote/"><strong>TLRY</strong></a>) shares rebounded slightly in recent weeks, but the company&rsquo;s per-share pricing still sits close to 52-week lows and even further from past highs pre-2020 when it traded north of $140. But stock suppression of this magnitude conceals Tilray&rsquo;s true long-term strength compared to other cannabis stocks.</p>



<p>One of those unique strengths is Tilray&rsquo;s expanding craft beer business. Since acquiring several brands from <strong>Anheuser-Busch</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/bud-stock-quote/"><strong>BUD</strong></a>) in 2023, Tilray <a href="https://www.bloomberg.com/news/articles/2024-01-09/craft-beer-growth-is-saving-tilray-from-cannabis-vegetable-woes">doubled its alcohol sales</a>, generating important sales diversification within the competitive cannabis market.</p>



<p>Tilray&rsquo;s craft beer forays are significant and often underestimated. As recreational cannabis legalization progresses through national legislative channels, Tilray&rsquo;s well-established production, distribution, and operational network positions it uniquely to capitalize on eventual legalization. Its newly bought infrastructure could be pivotal in distributing cannabis products nationwide and give Tilray a notable edge over competitors.</p>



<p>Tilray is building a $250 million cash reserve to <a href="https://investorplace.com/2024/06/is-tilray-stock-your-ticket-to-the-coming-u-s-cannabis-gold-rush/">fund strategic acquisitions</a> and expand its operations. While this move will dilute shares, it also creates further unique opportunities among cannabis stocks as Tilray builds and consolidates a US-based empire.</p>



<h2>KindlyMD (KDLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div><p>Including <strong>KindlyMD</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kdly-stock-quote/"><strong>KDLY</strong></a>) among cannabis stocks at 52-week lows is kind of cheating, as the company only just hit public markets. Still, shares have slid rapidly since IPO, dropping 22% from its initial $3 listing price. But the rapid downswing, as with Tilray, conceals KindlyMD&rsquo;s unique status amongst cannabis stocks.</p>



<p>KindlyMD is positioned at the intersection of two growing trends: the burgeoning medical cannabis sector and holistic treatments that integrate prescription medication with behavioral, mental therapy, and alternative solutions to &ldquo;<a href="https://kindlymd.com/about-us/">treat the whole person</a>, not just their symptoms.&rdquo;</p>



<p>Although its <a href="https://feeds.issuerdirect.com/news-release.html?newsid=8925359497374292">first earnings report</a> post-IPO showed a modest revenue of $829,000, this is more of a short-term challenge on the path to long-term success. The company has achieved several milestones that indicate significant potential for future growth. Notably, KindlyMD became Utah&rsquo;s first alternative medicine company to secure contracts under the state&rsquo;s insurance programs, including Medicare and Medicaid. It also signed a deal with <strong>Blue Cross Blue Shield</strong> and currently holds 16% of Utah&rsquo;s medical cannabis market.</p>



<h2>Valley National Bancorp (VLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/banks1600-300x169.jpg" alt="Image of a grey cityscape with a large corporate building that features the word bank on it"><div>Source: Shutterstock</div></div><p>As with KindlyMD, <strong>Valley National Bancorp</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/vly-stock-quote/"><strong>VLY</strong></a>)&nbsp;sits at the intersection of two unique sectors: cannabis and banking. Both sectors are facing unique challenges, though, contributing to Valley National&rsquo;s current per-share pricing woes.</p>



<p><a href="https://www.morningstar.com/stocks/xnas/vly/quote">Valley National trades</a> at a mere 0.6x book value and 8x earnings, making it both undervalued and often overlooked, considering its unique forays into <a href="https://www.retailbrew.com/series/spliff-and-mortar/stories/2023/03/30/dank-of-america-why-getting-dropped-by-a-bank-is-seen-as-a-rite-of-passage-for-cannabis-retailers">cannabis-based banking</a> as one of the few institutions happily servicing cannabis retailers. The bank&rsquo;s strong financial foundation is evident through its low <a href="https://www.morningstar.com/stocks/xnas/vly/valuation">debt-to-equity ratio</a> of just 0.56, significantly lower than the industry average of 1.2. This demonstrates Valley National&rsquo;s conservative leverage approach compared to its peers. Recent initiatives, such as the <a href="https://finance.yahoo.com/news/valley-national-vly-announces-share-161100413.html">stock buyback program</a> and a 6.07% <a href="https://www.morningstar.com/stocks/xnas/vly/dividends">trailing dividend yield</a>, further highlight the bank&rsquo;s robust financial health and commitment to returning value to shareholders.</p>



<p><a href="https://equityset.com/stocks/nasdaq-vly?tag=stock-analysis&amp;tab=sentiment">Analysts also see potential</a> in Valley National, setting an average price target of $8.06, which is about 6% above its current share price. Sentiment around the bank stock is improving, with 56% of analysts now recommending a &ldquo;hold,&rdquo; a significant shift from the 50% who advised selling in the previous period. This positive momentum suggests a promising outlook for Valley National as an undervalued investment opportunity among cannabis stocks.</p>



<p><em>On the date of publication, Jeremy Flint held no positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the <a href="http://InvestorPlace.com">InvestorPlace.com</a> <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em></p>
<div><p>Jeremy Flint, an MBA graduate and skilled finance writer, excels in content strategy for wealth managers and investment funds. Passionate about simplifying complex market concepts, he focuses on fixed-income investing, alternative investments, economic analysis, and the oil, gas, and utilities sectors. Jeremy&rsquo;s work can also be found at <a href="https://jeremyflint.work/">www.jeremyflint.work</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-cannabis-stocks-to-buy-at-a-52-week-low-in-july/">3 Cannabis Stocks to Buy at a 52-Week Low in July</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Cannabis Stocks to Buy at a 52-Week Low in July

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Kindly MD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/kdly-stock-quote/"><strong>KDLY</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Kindly MD reported earnings per share of -26 cents.</li><li>The company reported revenue of $639,057.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/kdly-stock-earnings-kindly-md-for-q2-of-2024/">KDLY Stock Earnings: Kindly MD Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

KDLY Stock Earnings: Kindly MD Reported Results for Q2 2024

KindlyMD GAAP EPS of -$0.26

Kindly MD, Inc. (KDLY) has provided an update. Kindly MD, Inc., a Utah-based company, is informing its investors and the broader investment communi...

Kindly MD, Inc. Embraces Social Media for Investor Updates

Kindly MD, Inc. ( ($KDLY) ) just unveiled an announcement. KindlyMD, a healthcare company focusing on integrated medical strategies, has launched a...

Kindly MD, Inc. Announces Stock Repurchase Program

Kindly MD, Inc. ( ($KDLY) ) has provided an announcement. Tim Pickett, CEO of Kindly MD, Inc., is presenting at the LD Micro Conference, sharing in...

Kindly MD CEO Presents at LD Micro Conference

KindlyMD (KDLY) is now contracted with Cigna (CI) Healthcare, after receiving additional credentialing. Cigna's innovative approach to behavioral h...

KindlyMD enters partnership with Cigna Healthcare

Reports Q3 revenue $647,867 vs. $869,268 last year. "We are pleased with the progress made during the third quarter to expand our credentialing and...

KindlyMD reports Q3 EPS (17c) vs. (11c) last year

KindlyMD GAAP EPS of -$0.17, revenue of $0.65M

CURLF

KDLY

RDDT

RIVN

STLA

TLRY

TSLA

Press Releases

KindlyMD to Present at Upcoming August 2024 Investor Conferences

KindlyMD Announces Second Quarter 2024 Financial Results and Provides Shareholder Update

Management

KindlyMD(TM) Appoints Nancy Pratt as Behavioral Health Program Director

KindlyMD to Participate in H.C. Wainwright's 26th Annual Global Investment Conference on September 9-11, 2024

KindlyMD(TM) Recognized with Healthcare AI Impact Award 2024

KindlyMD(TM) to Participate in Upcoming October Conferences

KindlyMD(TM) Announces Contract with United Healthcare Insurance, the Largest Health Insurer in the United States

KindlyMD(TM) Announces $500,000 Share Repurchase Program

Contracts

KindlyMD(R) Announces New Partnership With Cigna Healthcare to Further Expand Patient Care Accessibility

KindlyMD(R) Announces Third Quarter 2024 Financial Results

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

CareMax

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

Kindly MD

Interés en corto

Kindly MD (NASDAQ:KDLY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL